Small molecule · Cytotoxic, directed at DNA · developed by Avet Lifesciences
Carmustine is a nitrosourea alkylating agent that cross-links DNA and carbamoylates proteins, including DNA repair enzymes, producing cytotoxic effects. It crosses the blood-brain barrier readily. It is studied in pancreatic cancer and breast cancer, among other cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00814593 | Phase 2 | Brain and Central Nervous System Tumors | Withdrawn | LSTA |
| NCT04150042 | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Recruiting | MYGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adenocarcinoma of the BreastBRCA1 MutationBRCA2 MutationBreast Cancer MetastaticBreast Cancer Stage IVHER2 Negative Breast CarcinomaHER2-negative Breast CancerMetastatic Pancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaPALB2 Gene MutationPancreatic Acinar Cell CarcinomaPancreatic Adenocarcinoma MetastaticPancreatic CancerPancreatic Cancer Stage IV
Updated Oct 25, 2026.